Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 6/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352962 | 0.79 | HTR7 (0.69) | PTGS2HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL27876080 | 0.77 | HTR7 (0.67) | PTGS2HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL13039956 | 0.77 | HTR7 (0.67) | PTGS2HTR7HTR1AHTR2AHTR5A | |
| Hydrochloric Acid SCHEMBL27892728 | 0.75 | HTR7 (0.65) | PTGS2HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL7130590 | 0.75 | PTGS2 (0.60) | PTGS2HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL28281276 | 0.73 | PTGS2 (0.54) | PTGS2HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL6226663 | 0.71 | PTGS2 (0.49) | PTGS2HTR7HTR1AHTR6MAPK1 | |
| SCHEMBL8444831 | 0.71 | PTGS2 (0.60) | PTGS2HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL6700114 | 0.70 | CHKA (0.53) | PTGS2HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL3242006 | 0.69 | PTGS2 (1.00) | PTGS2MAPK1ALDH1A1EGFRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10702479-B2 | Pharmaceutical formulation comprising sembragiline | HOFFMANN-LA ROCHE INC. (US) | 2020-07-07 | — | — | US | disclosed |
| CN-110240557-A | Pyrrolidine derivative and application thereof | 广东东阳光药业有限公司 | 2019-09-17 | — | — | CN | disclosed |
| US-20180042853-A1 | PHARMACEUTICAL FORMULATION COMPRISING SEMBRAGILINE | HOFFMANN-LA ROCHE INC. (US) | 2018-02-15 | — | — | US | disclosed |
| EP-3273946-A1 | PHARMACEUTICAL FORMULATION COMPRISING SEMBRAGILINE | F. Hoffmann-La Roche AG (CH) | 2018-01-31 | — | — | EP | disclosed |
| US-9562009-B2 | Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide | HOFFMANN-LA ROCHE INC. (US) | 2017-02-07 | — | — | US | disclosed |
| WO-2016156124-A1 | PHARMACEUTICAL FORMULATION COMPRISING SEMBRAGILINE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-06 | — | — | WO | disclosed |
| EP-3063130-A1 | CRYSTALLINE FORMS OF A PYRROLIDONE DERIVATIVE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE AND PREPARATION THEREOF | F. Hoffmann-La Roche AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-20160237032-A1 | PROCESS TO MANUFACTURE N-[(3S)-1-[4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-5-OXO-PYRROLIDIN-3-YL]ACETAMIDE | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2015063001-A1 | CRYSTALLINE FORMS OF A PYRROLIDONE DERIVATIVE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE AND PREPARATION THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| JP-5366192-B2 | — | — | 2013-12-11 | — | — | JP | disclosed |
| WO-2006097197-A1 | METHOD FOR PREPARING ENANTIOMERICALLY PURE 4-PYRROLIDINOPHENYL, BENZYL, ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097270-A1 | METHOD OF PREPARATION OF PURE 4-PYRROLIDINOPHENYLBENZYL ETHER DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | IDING HANS | 2006-06-08 | — | — | US | disclosed |
| US-7037935-B2 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-05-02 | — | — | US | disclosed |
| CN-1681779-A | 4-pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| EP-1542971-A1 | 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES | F. Hoffmann-La Roche Ltd. (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040116707-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | disclosed |
| US-20040097578-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-05-20 | — | — | US | disclosed |
| WO-2004026826-A1 | 4-PYRROLIDINO-PHENYL-BENZYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702479-B2 | Pharmaceutical formulation comprising sembragiline | SLC6A11, SLC10A1, CYP3A7 | PTGS2 3920/4885HTR7 21/4885HTR1A 573/4885 |
| US-20180042853-A1 | PHARMACEUTICAL FORMULATION COMPRISING SEMBRAGILINE | SLC6A11, SLC10A1, CYP3A7 | PTGS2 3920/4885HTR7 21/4885HTR1A 573/4885 |
| US-20040106650-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | PTGS2 1507/4885HTR7 217/4885HTR1A 106/4885 |
| US-20060122235-A1 | Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide | MAOA, MAOB, PNPO | PTGS2 1192/4885HTR7 317/4885HTR1A 83/4885 |
| US-20160237032-A1 | PROCESS TO MANUFACTURE N-[(3S)-1-[4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-5-OXO-PYRROLIDIN-3-YL]ACETAMIDE | NANS, PFAS, ALDH18A1 | PTGS2 689/4885HTR7 2829/4885HTR1A 1346/4885 |
| US-20040097578-A1 | 4-Pyrrolidino-phenyl-benzyl ether derivatives | MAOB, MAOA, COMT | PTGS2 1197/4885HTR7 273/4885HTR1A 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.